Furthermore, we observed activity of this drug combination even in difficult to treat AML subtypes, such as AML with complex cytogenetics (Figure 9A), with mutated TP53 (Figure 9C), or with venetoclax resistance (Figure 9E). This evidence concerns the gene TP53 and acute myeloid leukemia.